AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Change in Account Payables of -$405000.0 for Q1 2026, down 65.98% year-over-year from -$1.2 million in Q1 2025, and down 150.94% quarter-over-quarter from $795000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Change in Account Payables (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Change in Account Payables for 6 consecutive years, with -$405000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 65.98% year-over-year to -$405000.0; the TTM figure through Mar 2026 stood at -$457000.0 (down 171.41% YoY), while the FY2025 annual figure was -$296000.0, down 146.18% from the prior year.
- Change in Account Payables declined to -$405000.0 in Q1 2026 per ANTX's latest filing, from $795000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q3 2023 and bottomed at -$2.1 million in Q4 2023.
- Historically, Change in Account Payables has averaged $175882.4 across 5 years, with a median of -$171000.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 1065.5% in 2023 and fell as far as 409.4% in 2023.
- AN2 Therapeutics' Change in Account Payables stood at $681000.0 in 2022, then plunged by 409.4% to -$2.1 million in 2023, then soared by 176.22% to $1.6 million in 2024, then sank by 50.5% to $795000.0 in 2025, then sank by 150.94% to -$405000.0 in 2026.
- Business Quant data shows ANTX's Change in Account Payables at -$405000.0 in Q1 2026, $795000.0 in Q4 2025, and $113000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -998,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -998,000.00 |
| Mar 31, 2026 | -405,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | -960,000.00 |
| Mar 31, 2025 | -244,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -548,000.00 |
| Mar 31, 2024 | -243,000.00 |
| Dec 31, 2023 | -2.11 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | -414,000.00 |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 681,000.00 |
| Sep 30, 2022 | -171,000.00 |
| Jun 30, 2022 | 441,000.00 |
| Mar 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | -946,000.00 |
| Sep 30, 2021 | 711,000.00 |